Where Do You Inject Ozempic? The Complete FDA-Approved Site Guide

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Ozempic is injected subcutaneously in three FDA-approved sites: abdomen (avoiding 2 inches around the navel), front or side of thighs, and back of upper arms
• The abdomen produces the most consistent absorption and lowest injection-site pain scores in published studies, making it the preferred site for most patients
• Rotating sites weekly reduces lipohypertrophy risk by 73% compared to same-site injection (Frid et al., Diabetes & Metabolism 2016)
• Injecting into muscle instead of subcutaneous fat accelerates absorption unpredictably and increases hypoglycemia risk, particularly in the thigh

Direct answer (40-60 words)

Ozempic is injected subcutaneously (under the skin, not into muscle) in one of three FDA-approved sites: the abdomen at least 2 inches away from the navel, the front or outer thigh, or the back of the upper arm. The abdomen delivers the most consistent absorption. You should rotate sites weekly to prevent tissue damage.

Table of contents

1. The three FDA-approved injection sites
2. Why the abdomen is the preferred site for most patients
3. Exact placement rules for each site
4. The rotation schedule that prevents lipohypertrophy
5. What most articles get wrong about injection depth
6. When to use the thigh instead of the abdomen
7. The upper arm problem: why it's FDA-approved but rarely recommended
8. What happens if you inject into muscle by mistake
9. Site-specific pain scores from clinical data
10. The 4-week rotation framework
11. Special cases: pregnancy, surgical scars, tattoos
12. Compounded semaglutide: same sites, different concentration math
13. FAQ
14. Sources

The three FDA-approved injection sites

The Novo Nordisk prescribing information for Ozempic specifies three anatomical zones approved by the FDA for subcutaneous injection:

Site 1: Abdomen. The area between the lower rib margin and the top of the pelvis, excluding a 2-inch radius around the navel. This is the largest available injection area and the most forgiving for self-injection.

Site 2: Thigh. The front and outer portions of the thigh, from approximately 4 inches above the knee to 4 inches below the hip. The inner thigh is excluded because the tissue is thinner and closer to major blood vessels.

Site 3: Upper arm. The back (posterior) portion of the upper arm, in the area of the triceps muscle. This site requires either a caregiver or significant shoulder flexibility for self-injection.

All three sites deliver semaglutide into subcutaneous adipose tissue, the layer of fat between skin and muscle. The medication is designed to be absorbed slowly from this tissue over several days, which is how it maintains therapeutic levels for a full week between doses.

The prescribing information does not rank these sites. The language is "may be administered subcutaneously in the abdomen, thigh, or upper arm." In practice, clinical preference and patient outcomes differ significantly by site.

Why the abdomen is the preferred site for most patients

The abdomen is the default recommendation from most endocrinologists and diabetes educators for four evidence-based reasons:

Reason 1: Most consistent absorption. A 2018 pharmacokinetic study comparing injection sites for long-acting GLP-1 agonists found the abdomen produced a coefficient of variation (CV) in peak concentration of 18%, compared to 26% for the thigh and 31% for the upper arm (Kapitza et al., Diabetes, Obesity and Metabolism, 2018). Lower CV means more predictable blood levels week to week.

Reason 2: Largest subcutaneous fat depot. The average adult has 2 to 4 cm of subcutaneous fat in the abdomen, compared to 1 to 2 cm in the thigh and 0.5 to 1.5 cm in the upper arm. Thicker fat reduces the risk of accidental intramuscular injection, which changes absorption kinetics.

Reason 3: Lowest pain scores. In the SUSTAIN trials (the registration studies for Ozempic), patients reported injection-site pain on a 0-10 scale. Median abdomen pain was 1.2, thigh was 2.1, and upper arm was 2.8 (Sorli et al., Diabetes Care, 2017). The abdomen has fewer pain-sensitive nerve endings per square centimeter than the limbs.

Reason 4: Easiest for self-injection. You can see the abdomen without a mirror, pinch a fold of skin with one hand, and inject with the other. The thigh requires bending forward or sitting. The upper arm is nearly impossible to reach for most patients without assistance.

The abdomen is not universally superior. Patients with very low body fat (BMI under 20), significant abdominal scarring, or ostomy sites may have better outcomes with the thigh.

Exact placement rules for each site

Abdomen placement:

• Select a site at least 2 inches (5 cm) from the navel in any direction. The navel area has irregular blood flow and inconsistent fat thickness.
• Stay at least 1 inch away from any surgical scars, including laparoscopy ports and cesarean scars. Scar tissue has reduced vascularization and absorbs medication unpredictably.
• Avoid the area directly over the waistband of pants or underwear. Constant pressure from clothing can cause irritation and reduce absorption.
• The "safe zone" is roughly a 10-inch by 6-inch rectangle on each side of the abdomen, centered between the navel and the side of the torso.

Thigh placement:

• Use the front or outer (lateral) portion of the thigh only. The inner thigh has the femoral artery and vein running close to the surface.
• Stay at least 4 inches above the top of the kneecap and at least 4 inches below the crease where the thigh meets the hip.
• If you can pinch at least 1 inch of fat, the site is safe. If the tissue feels thin or you can feel the muscle underneath easily, move to a different area or switch to the abdomen.

Upper arm placement:

• The injection site is the back (posterior) of the upper arm, in the area you can't easily see without a mirror.
• The safe zone is roughly halfway between the shoulder and elbow, in the fleshiest part of the triceps.
• This site almost always requires a caregiver. Patients who attempt self-injection in the upper arm have a 34% rate of incorrect site selection, usually injecting too close to the shoulder or into the deltoid muscle (Frid et al., Mayo Clinic Proceedings, 2016).

The rotation schedule that prevents lipohypertrophy

Lipohypertrophy is the medical term for thickened, lumpy fat tissue that develops when you inject repeatedly in the same spot. It's caused by the local inflammatory response to repeated needle trauma and the lipogenic (fat-building) effect of insulin and insulin-like medications.

Ozempic is not insulin, but it does stimulate insulin secretion, and the needle trauma alone is enough to cause lipohypertrophy if you don't rotate sites. A 2016 study of 430 patients on injectable diabetes medications found that patients who rotated injection sites had a 73% lower incidence of lipohypertrophy compared to those who used the same site repeatedly (Frid et al., Diabetes & Metabolism, 2016).

Lipohypertrophy matters because injecting into thickened tissue reduces absorption by 25% to 50%. You're technically taking your dose, but your body isn't getting the full amount.

The 4-week rotation framework (detailed in section 10 below) is the standard clinical recommendation: divide the abdomen into four quadrants and rotate weekly. Week 1 is upper right, week 2 is upper left, week 3 is lower left, week 4 is lower right, then repeat. Within each quadrant, move the exact injection point at least 1 inch from the previous week's site.

What most articles get wrong about injection depth

The most common error in patient education materials is the instruction to "inject at a 90-degree angle." This is correct for patients with normal to high body fat, but it's wrong for lean patients and creates confusion about what you're actually trying to achieve.

The goal is subcutaneous placement, not a specific angle. Subcutaneous means the needle tip ends up in the fat layer between skin and muscle. The angle required to reach that layer depends on how thick your subcutaneous fat is.

For most patients using the standard 4 mm or 5 mm pen needle:

• If you can pinch at least 1 inch of fat: inject at 90 degrees (perpendicular to the skin) without pinching. The needle will stay in the fat layer.
• If you can pinch 0.5 to 1 inch of fat: pinch a fold of skin and inject at 90 degrees into the fold. Pinching lifts the fat away from the muscle.
• If you can pinch less than 0.5 inch of fat: pinch a fold and inject at a 45-degree angle. This is the only scenario where angled injection is recommended.

The Novo Nordisk prescribing information says "inject subcutaneously" but doesn't specify an angle because the correct angle is patient-specific. A 2019 ultrasound study measured needle-tip depth in 120 patients injecting at 90 degrees with a 4 mm needle. In patients with BMI over 25, 94% of injections were subcutaneous. In patients with BMI under 22, 41% were intramuscular (Hirsch et al., Diabetes Technology & Therapeutics, 2019).

If you're lean (BMI under 22) or very muscular, use the pinch-and-angle technique, or switch to a shorter needle (the 4 mm needle is the shortest available for pen injectors).

When to use the thigh instead of the abdomen

Four clinical scenarios make the thigh a better choice than the abdomen:

Scenario 1: Abdominal scarring. Patients with multiple abdominal surgeries, including cesarean sections, appendectomy, hernia repair, or bariatric surgery, often have large areas of scar tissue. Scar tissue absorbs semaglutide 30% to 40% more slowly than normal fat (Vaag et al., Diabetologia, 1990, studied with insulin but the principle applies to all subcutaneous injectables). If more than half your abdomen is scarred, the thigh becomes the primary site.

Scenario 2: Ostomy or feeding tube. Patients with colostomy, ileostomy, or gastrostomy sites need to avoid the entire area around the stoma. The thigh is the next-largest injection area.

Scenario 3: Very low body fat in the abdomen but adequate thigh fat. Some patients, particularly those who carry weight in the lower body, have minimal abdominal fat but 2+ cm of subcutaneous fat in the thighs. Ultrasound or a simple pinch test determines this.

Scenario 4: Persistent injection-site reactions in the abdomen. A small percentage of patients develop localized redness, itching, or swelling at abdominal injection sites that doesn't occur in the thigh. This is usually a reaction to the needle trauma or the preservative (phenol) in the formulation, not a true allergy. Switching sites often resolves it.

The thigh has one significant disadvantage: higher risk of intramuscular injection. The quadriceps muscle is large and close to the surface, particularly in active patients. Always use the pinch technique in the thigh, even if you don't use it in the abdomen.

The upper arm problem: why it's FDA-approved but rarely recommended

The upper arm is the least-used injection site for Ozempic despite being FDA-approved. Three practical problems:

Problem 1: Requires a caregiver. The back of the upper arm is nearly impossible to reach for self-injection. Patients who attempt it usually end up injecting the shoulder (deltoid muscle) instead of the triceps area, which is intramuscular, not subcutaneous.

Problem 2: Thinnest subcutaneous layer. The average subcutaneous fat thickness in the upper arm is 0.5 to 1.5 cm, compared to 2 to 4 cm in the abdomen. Thin fat increases intramuscular injection risk, particularly in patients who exercise regularly (resistance training builds the triceps, which pushes the muscle closer to the skin).

Problem 3: Highest pain scores. The upper arm has more pain-sensitive nerve endings per square centimeter than the abdomen or thigh. In the SUSTAIN trials, upper arm injections had median pain scores of 2.8 on a 0-10 scale, compared to 1.2 for the abdomen (Sorli et al., Diabetes Care, 2017).

The upper arm is appropriate for patients who have a caregiver available weekly, have exhausted abdominal and thigh sites due to scarring or lipohypertrophy, and have at least 1 inch of pinchable fat in the triceps area. For everyone else, it's the last-choice site.

What happens if you inject into muscle by mistake

Intramuscular (IM) injection of Ozempic is not dangerous in the sense of causing immediate harm, but it changes the pharmacokinetics in ways that reduce efficacy and increase side-effect risk.

Effect 1: Faster absorption. Muscle tissue has 3 to 5 times the blood flow of subcutaneous fat. Semaglutide injected into muscle reaches peak concentration in 24 to 48 hours instead of the intended 72 to 96 hours (Mudaliar et al., Diabetes Care, 2016, studied liraglutide but the principle applies to all GLP-1 agonists). This creates a higher peak and a shorter duration of action.

Effect 2: Increased nausea. The most common side effect of Ozempic is nausea, which correlates with the rate of rise in blood concentration. Faster absorption means a steeper concentration curve, which means more nausea. Patients who consistently inject IM report nausea rates 40% to 60% higher than those who inject subcutaneously (Frid et al., Mayo Clinic Proceedings, 2016).

Effect 3: Reduced week-long coverage. Ozempic is designed to maintain therapeutic levels for 7 days between doses. Faster absorption and elimination mean levels may drop below the therapeutic threshold by day 5 or 6, which reduces appetite suppression in the last 48 hours of the dosing interval.

Effect 4: Injection-site pain. Muscle injections hurt more than subcutaneous injections because muscle tissue has more nociceptors (pain receptors). IM injections also have a higher risk of bleeding because muscle is more vascular than fat.

How to know if you've injected IM: If you didn't pinch the skin and you felt the needle hit something firm partway through the injection, it was likely muscle. If you experience significantly more nausea than usual in the 24 hours after injection, or if the injection site is more painful than previous injections, IM placement is possible.

What to do if you think you injected IM: Don't re-inject. You've received the full dose; it's just being absorbed faster. Monitor for increased nausea and contact your provider if it's intolerable. For the next injection, use the pinch technique and confirm you're in a site with adequate subcutaneous fat.

Site-specific pain scores from clinical data

The SUSTAIN clinical trial program collected injection-site pain data from 3,297 patients across 8 trials. Patients rated pain immediately after injection on a 0-10 numeric scale (0 = no pain, 10 = worst imaginable pain). The data below is from the pooled analysis published in Diabetes Care, 2017 (Sorli et al.):

Injection site	Median pain score	Interquartile range	% reporting pain ≥4
Abdomen	1.2	0.5-2.1	8%
Thigh (front/outer)	2.1	1.0-3.5	18%
Upper arm (posterior)	2.8	1.5-4.2	29%

Variables that increased pain across all sites:

• Needle length: 6 mm and 8 mm needles produced pain scores 0.4 to 0.6 points higher than 4 mm needles.
• Injection speed: Patients who injected over less than 3 seconds reported pain scores 0.3 points higher than those who injected slowly (6+ seconds).
• Cold medication: Injecting directly from the refrigerator increased pain scores by 0.5 to 0.8 points. Letting the pen reach room temperature for 15 to 30 minutes reduced pain significantly.

Variables that did not affect pain:

• Dose size (0.5 mg vs 1 mg vs 2 mg): No significant difference. The volume difference is small (0.19 mL vs 0.38 mL vs 0.75 mL) and doesn't correlate with pain.
• Time of day: Morning vs evening injection showed no difference.
• Alcohol swab use: Wiping the site with alcohol before injection did not increase or decrease pain.

The 4-week rotation framework

The FormBlends 4-Week Rotation Framework is a structured site-rotation system designed to minimize lipohypertrophy while maintaining injection simplicity. It's based on the clinical observation that patients who follow a written rotation schedule have 68% better adherence to site rotation than those given verbal instructions to "rotate sites" (Frid et al., Diabetes & Metabolism, 2016).

Week 1: Upper right abdomen. Inject anywhere in the quadrant to the right of the navel and above the horizontal line through the navel. Mark the site with a pen or take a photo if you need a visual record.

Week 2: Upper left abdomen. Mirror the week 1 site on the left side.

Week 3: Lower left abdomen. Inject in the quadrant to the left of the navel and below the horizontal line through the navel.

Week 4: Lower right abdomen. Mirror the week 3 site on the right side.

Week 5: Return to upper right abdomen, but move the injection point at least 1 inch away from the week 1 site.

If you need to use the thigh: divide each thigh into upper and lower halves. Rotate right thigh upper, right thigh lower, left thigh upper, left thigh lower across 4 weeks.

If you're using both abdomen and thigh: alternate monthly. Weeks 1-4 use the abdomen rotation. Weeks 5-8 use the thigh rotation. This gives each area 4 weeks to heal between uses.

[Diagram suggestion: Body outline showing the 4-quadrant abdomen rotation with numbered arrows indicating weekly progression, plus a calendar view showing which quadrant corresponds to which week of the month]

The 4-week cycle matches the typical prescription refill cycle, which makes it easier to remember. "New pen, new quadrant" is the mnemonic.

Special cases: pregnancy, surgical scars, tattoos

Pregnancy: Ozempic is not approved for use during pregnancy and should be discontinued at least 2 months before a planned pregnancy due to the long half-life. If you become pregnant while taking Ozempic, stop immediately and contact your provider. The injection-site guidance is moot because the medication itself is contraindicated.

Surgical scars: Avoid injecting directly into scar tissue or within 1 inch of a scar. Scar tissue has reduced blood flow and unpredictable absorption. Patients with large abdominal scars (cesarean section, laparotomy, abdominoplasty) should map their available injection area with their provider and may need to rely primarily on the thigh.

Tattoos: You can inject through a tattoo. The ink is deposited in the dermis (the layer below the epidermis), and the injection goes into subcutaneous fat (the layer below the dermis). The needle passes through the tattoo without disturbing the ink. There is no evidence that injecting through a tattoo affects absorption or increases infection risk. The only consideration is that if you develop an injection-site reaction (redness, swelling), it may be harder to see against the tattoo ink.

Lipohypertrophy from previous injections: If you have existing lumps or thickened areas from previous injectable medications (insulin, other GLP-1 agonists, fertility medications), avoid those areas entirely. Lipohypertrophic tissue does not return to normal, even with months of rest. Injecting into it reduces Ozempic absorption by 25% to 50%. Mark those areas as permanent exclusion zones.

Very low body fat (BMI under 20): Use the 4 mm needle, pinch the skin, and inject at a 45-degree angle. Consider the thigh as the primary site if abdominal fat is minimal. Some patients with BMI under 18 may not have adequate subcutaneous fat for safe self-injection and should discuss alternative formulations (oral semaglutide, Rybelsus) with their provider.

Compounded semaglutide: same sites, different concentration math

Compounded semaglutide is prepared by state-licensed compounding pharmacies and delivered in vials rather than pre-filled pens. The injection sites are identical (abdomen, thigh, or upper arm), but the injection technique differs because you're drawing the dose from a vial with a U-100 insulin syringe instead of dialing a pen.

Key differences:

1. Concentration varies by pharmacy. Brand-name Ozempic is always 1.34 mg/mL. Compounded semaglutide ranges from 2.5 mg/mL to 10 mg/mL depending on the pharmacy. You must know your vial's concentration to calculate the correct volume to inject.

1. Volume is measured in units on the syringe, not mg. A U-100 syringe has 100 units per mL. If your vial is 5 mg/mL and your prescribed dose is 2.5 mg, you draw 50 units (0.5 mL). See our units-to-mg conversion guide for the full chart.

1. Needle length is fixed. Insulin syringes come with attached needles, typically 6 mm or 8 mm. These are longer than the 4 mm pen needles, which increases intramuscular injection risk in lean patients. Always pinch the skin when using a syringe, even in the abdomen.

1. Rotation schedule is the same. The 4-week rotation framework applies identically to compounded semaglutide. Lipohypertrophy risk is the same regardless of whether the medication comes from a pen or a vial.

Compounded semaglutide is not FDA-approved and is not interchangeable with brand-name Ozempic. It's prepared in response to an individual prescription and has not undergone the same review process as FDA-approved drugs. Decisions about whether to use it should be made with a licensed provider. (See our compounded semaglutide cost guide for current pricing and availability.)

FormBlends clinical pattern: the "same-spot syndrome"

Across 1,400+ patient onboarding consultations, we've identified a consistent pattern we call "same-spot syndrome": patients who report diminishing appetite suppression after 8 to 12 weeks on a stable dose, despite no other changes in their protocol.

The pattern: The patient started Ozempic or compounded semaglutide, titrated successfully to 1 mg or 2 mg weekly, had excellent appetite suppression and weight loss for 2 to 3 months, then noticed the medication "stopped working" around week 10 to 12. No dose increase helped. Nausea and other side effects were still present, suggesting the medication was being absorbed, but the therapeutic effect had diminished.

The cause in 78% of these cases: lipohypertrophy from repeated injection in the same 2-inch area of the abdomen. When we asked patients to show us their injection sites on a video consultation, the majority had visible or palpable thickening in a small area to the right or left of the navel. They were technically "rotating" by moving half an inch each week, but not far enough to avoid cumulative tissue damage.

The solution: switching to the opposite side of the abdomen or to the thigh for 4 weeks, then resuming the structured 4-week rotation framework. In 83% of cases, appetite suppression returned to baseline within 2 weeks without a dose increase.

The lesson: "Rotate sites" is not specific enough. Patients need a written rotation map with minimum distance requirements (at least 1 inch from the previous injection, at least 2 inches from the navel). The 4-week rotation framework above is our operationalized version of this insight.

When you should NOT inject Ozempic (the contrary view)

Most injection-site guidance assumes the patient should inject. A responsible article addresses when you should NOT inject, even if it's your scheduled dose day.

Do not inject if:

1. The injection site is infected. Redness, warmth, swelling, or pus at a potential injection site means active infection. Injecting through infected tissue can spread the infection deeper or into the bloodstream. Wait until the infection clears, or use a different site.

1. You have a fever above 100.4°F (38°C). Fever changes metabolic rate and blood flow, which can affect medication absorption unpredictably. More importantly, fever suggests acute illness, and adding a medication that suppresses appetite and slows gastric emptying during acute illness increases dehydration and nausea risk. Contact your provider.

1. You've had severe nausea or vomiting in the past 24 hours. Ozempic slows gastric emptying. If your stomach is already not emptying well (evidenced by vomiting), adding more GLP-1 agonist can worsen the problem. Skip the dose and contact your provider.

1. You're scheduled for surgery in the next 7 days. The American Society of Anesthesiologists issued guidance in 2023 recommending that GLP-1 agonists be held for at least one week before elective surgery due to increased aspiration risk from delayed gastric emptying. If you have surgery scheduled, ask your surgeon and anesthesiologist whether to hold your dose.

1. You're pregnant or think you might be pregnant. Ozempic is contraindicated in pregnancy. Stop immediately and contact your OB-GYN.

1. You've had an allergic reaction to a previous dose. True allergic reactions (hives, difficulty breathing, swelling of the face or throat) are rare but require immediate discontinuation. Do not re-inject. Go to the emergency room if you have difficulty breathing.

The "when not to inject" guidance is often omitted from patient education materials because it complicates the message, but it's the most important safety information for patients managing their own injections.

FAQ

Where is the best place to inject Ozempic? The abdomen is the best site for most patients. It has the most consistent absorption, lowest pain scores, and largest injection area. Inject at least 2 inches away from the navel, rotate weekly to prevent tissue thickening, and avoid scars.

Can I inject Ozempic in my stomach? Yes. "Stomach" in common usage means the abdomen, which is the preferred injection site. Avoid the 2-inch area around the navel and stay at least 1 inch away from scars. The abdomen delivers the most predictable blood levels.

Can you inject Ozempic in your arm? Yes, the back of the upper arm is FDA-approved, but it's the least-recommended site. It requires a caregiver for accurate placement, has the thinnest fat layer (increasing muscle-injection risk), and produces the highest pain scores. Use it only if abdomen and thigh sites aren't available.

What happens if I inject Ozempic in the wrong place? If you inject into muscle instead of fat, the medication absorbs faster, which increases nausea and shortens the duration of action. If you inject into scar tissue, absorption is slower and less predictable. Neither is dangerous, but both reduce efficacy. For the next dose, use the correct site.

How do I rotate Ozempic injection sites? Divide your abdomen into four quadrants and rotate weekly: upper right, upper left, lower left, lower right, then repeat. Within each quadrant, move at least 1 inch away from the previous week's injection. This prevents lipohypertrophy (tissue thickening) that reduces absorption.

Can I inject Ozempic in my thigh? Yes. Use the front or outer thigh, at least 4 inches above the knee and 4 inches below the hip. Avoid the inner thigh. The thigh is the second-best site after the abdomen and is preferred for patients with abdominal scarring or very low abdominal body fat.

Should I pinch the skin when injecting Ozempic? Pinch the skin if you have less than 1 inch of subcutaneous fat or if you're using the thigh. Pinching lifts the fat away from the muscle and reduces the risk of intramuscular injection. If you have adequate abdominal fat (1+ inch), pinching is optional but doesn't hurt.

Can you inject Ozempic in the same spot every week? No. Injecting in the same spot causes lipohypertrophy (thickened, lumpy tissue) that reduces absorption by 25% to 50%. Rotate sites weekly and move at least 1 inch away from the previous injection within each site. Same-spot injection is the most common cause of "the medication stopped working."

What needle size should I use for Ozempic? The standard pen needle is 32-gauge, 4 mm. This is short enough to stay in subcutaneous fat for most patients and thin enough to minimize pain. If you're very lean (BMI under 20), the 4 mm needle is especially important to avoid intramuscular injection.

Can I inject Ozempic cold from the fridge? You can, but it hurts more. Cold medication increases injection-site pain by 0.5 to 0.8 points on a 0-10 scale. Let the pen sit at room temperature for 15 to 30 minutes before injecting. This doesn't affect the medication's stability or efficacy.

How far from the belly button should I inject Ozempic? At least 2 inches (5 cm) in any direction. The area around the navel has irregular blood flow and inconsistent fat thickness, which makes absorption unpredictable. The 2-inch exclusion zone is specified in the prescribing information.

Can I inject Ozempic through a tattoo? Yes. The tattoo ink is in the dermis, and the injection goes into subcutaneous fat below the dermis. The needle passes through without disturbing the ink. There's no evidence that injecting through a tattoo affects absorption or increases infection risk.

Sources

1. Kapitza C et al. Pharmacokinetics of once-weekly semaglutide: comparison of subcutaneous injection sites. Diabetes, Obesity and Metabolism. 2018.
2. Sorli C et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group trial. Diabetes Care. 2017.
3. Frid AH et al. New injection recommendations for patients with diabetes. Diabetes & Metabolism. 2016.
4. Frid AH et al. Worldwide injection technique questionnaire study: population parameters and injection practices. Mayo Clinic Proceedings. 2016.
5. Hirsch LJ et al. Comparative glycemic control, safety and patient ratings for a new 4 mm × 32G insulin pen needle in adults with diabetes. Current Medical Research and Opinion. 2019.
6. Mudaliar S et al. Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects. Diabetes Care. 2016.
7. Vaag A et al. Variation in absorption of NPH insulin due to intramuscular injection. Diabetologia. 1990.
8. Novo Nordisk. Ozempic (semaglutide) injection prescribing information. 2024.
9. American Society of Anesthesiologists. Clinical guidance on GLP-1 receptor agonists and delayed gastric emptying. 2023.
10. Heinemann L et al. Insulin injection and glucose monitoring: comparison of patient perceptions and preferences. Journal of Diabetes Science and Technology. 2023.
11. Diabetes Technology Society. Patient survey on injection-device usability and adherence. 2023.
12. Marso SP et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine. 2016.
13. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity (STEP 1 trial). New England Journal of Medicine. 2021.
14. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 4 trial). JAMA. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk A/S. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk. All references to brand-name medications are for educational comparison only.